Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 8,135 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Sarcoma
Interventions: Rexin-G; Genetic
Lead sponsor: Epeius Biotechnologies; Industry
Eligibility: 10 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: San Marino, California • Santa Monica, California

Conditions: Solid Tumors, Lymphoma
Interventions: AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide); Drug
Lead sponsor: Arno Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Scottsdale, Arizona • Columbus, Ohio

Conditions: Prion Disease
Interventions: PrP-siRNA; Drug
Lead sponsor: Broad Institute of MIT and Harvard; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Rochester, Minnesota • New York, New York + 2 more

Conditions: Clinical Pharmacology, Healthy Volunteer Study
Interventions: Placebo, Pomalidomide, Moxifloxacin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Glaucoma
Interventions: Restasis, Endura (artificial tears); Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: SARS-CoV Infection, Covid19
Interventions: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination); Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 12 Years and older
Enrollment: 33,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 144
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more

Conditions: Squamous NSCLC
Interventions: CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg, CV09070101 mRNA vaccine (CVHNLC) 400 µg; Biological
Lead sponsor: CureVac; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Fairfax, Virginia • Richmond, Virginia

Conditions: Heart Failure
Interventions: Immediate release torsemide 20mg tablet, Extended release torsemide 24mg tablet; Drug
Lead sponsor: Sarfez Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
Interventions: Pregabalin, Duloxetine, Placebo; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Boston, Massachusetts • New York, New York • Rochester, New York + 4 more

Conditions: Recurrent Pericarditis
Interventions: KPL-914; Drug
Lead sponsor: Kiniksa Pharmaceuticals (UK), Ltd.; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Washington D.C., District of Columbia • DeLand, Florida • Jacksonville, Florida + 11 more

Conditions: Healthy
Interventions: Islatravir (ISL), Lamivudine (3TC); Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Diabetes, Type 1 Diabetes, Young Adult, Diabetes Mellitus
Interventions: T1D-CATCH; Behavioral
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 35 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: Lorlatinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Migraine Disorders
Interventions: gammaCore Sapphire active, gammaCore Sapphire Sham; Device
Lead sponsor: ElectroCore INC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 30
States / cities: Scottsdale, Arizona • Carlsbad, California • Palo Alto, California + 27 more

Conditions: Pharyngitis
Interventions: valdecoxib, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 2
States / cities: Storrs, Connecticut • Boca Raton, Florida

Conditions: Non Infectious Uveitis
Interventions: DE-109 Intravitreal Injections, Sham Procedure, DE-109 Intravitreal Injections (Open Label); Drug · Other
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 38
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more

Conditions: Cognition Disorders, Brain Pathology, Physical Disability, Physical Activity, Aging
Interventions: Aerobic Activity, Resistance Training, Yoga, Health Education; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years to 80 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: LY03005, Pristiq; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Malignant Melanoma
Interventions: Atezolizumab, Cobimetinib, Vemurafenib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Sarasota, Florida + 3 more

Conditions: Head and Neck Cancer
Interventions: Gemcitabine, Pemetrexed, Carboplatin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sepsis
Interventions: Ketamine, Normal Saline placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 21 Years to 100 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions: Nicotine Replacement Patch; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Macular Degeneration
Interventions: Rituximab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 41 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alcohol Exposed Pregnancy, Unplanned Pregnancy, Alcohol Use, Unspecified, Contraception Use, Sexual Behavior
Interventions: CARRII Native Rapid Pilot Testing; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Search by objective public record fields.

Safety and Efficacy Study Using Rexin-G for Sarcoma

Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma

PrP-targeting siRNA Safety & Mechanism Study

A Phase 1 QT Study in Healthy Male Subjects

Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

A Pilot Study of KPL-914 in Recurrent Pericarditis

A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)

T1DTechCHW: Enhancing the Community Health Worker Model to Promote Diabetes Technology Use in Young Adults From Underrepresented Minority Groups

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines

A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

A Precision Rehabilitation Approach to Counteract Age-Related Cognitive Declines

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients

Immunomodulatory Properties of Ketamine in Sepsis

Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients

Treatment -Resistant Neovascular Age-Related Macular Degeneration

Optimizing a Digital AEP Risk Intervention With Native Women and Communities